Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an ...

Research discoveries leading to the development of new pharmaceutical compounds are notoriously difficult to translate into clinical practice.1 Drug repurposing provides a strategy to identify ...

The National Institutes of Health office responsible for issuing federal guidelines related to treatment of HIV and AIDS ...

Side effects of the drug, tested as both a weekly injection and a daily pill, were mostly gastrointestinal with rates similar ...

We write to highlight an urgent, yet preventable public health tragedy unfolding in the Ecuadorian Amazon. In May, 2025, eight Indigenous Achuar children from Taisha—an Amazonic village from the ...

People who received higher doses of amycretin as a weekly injection lost 24.3 per cent of their body weight after 36 weeks of ...

A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few ...

Data supports the potential of future indication expansion for the MiniMed™ 780G system. LENNY trial results published in ...

Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose ...